AIPAC results are more significant than you think. If NSCLC results are as good as expected we could have three registrational trials running in major indications within twelve months, with at least one of them on a fast track. I doubt Marc would take a low ball offer with this kind of potential. But they will need more money from somewhere.
Buyout, deal, major capital raise? Something has to give within 12 months.
Marc has also talked about broadening the trial base. This will also be very interesting because now they have a much better idea of which cancer patients will benefit.
It's all good for patient Immuteper's, Imo.
Ann: New & significant data from AIPAC phase 2b trial in MBC, page-12
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $581.0M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 41.0¢ | 39.5¢ | $1.515M | 3.783M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 115519 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.5¢ | 37481 | 2 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |